Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 77Nivolumab 64Ipilimumab 40Specimen Handling 33Magnetic Resonance Spectroscopy 27Cyclophosphamide 26Biopsy 20cemiplimab 16fludarabine 14Radiosurgery 14relatlimab 13CTLA-4 Antigen 13binimetinib 12Opdualag 12trametinib 11fludarabine phosphate 11avelumab 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8atezolizumab 8Radiotherapy 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lidocaine, Prilocaine Drug Combination × Dermatologic × 90 days × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡